Orbomed - office based hysteroscopy

  • 375 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
375
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. OrbomedEARLY DIAGNOSIS – TIMELY CURE
  • 2. Orbomed teamVitaly Vishnepolsky, MBA CEO Dr. Vadim Sigalov, MDChief Business consultant Chief Medical consultant Ksenia Chagan, MBA Igor Shcherback, PhD Biotech advisor Physics advisor
  • 3. Hysteroscopy: background• Gold standard for detection of intrauterine pathology• Safe and simple procedure for outpatient clinics
  • 4. Hysteroscopy: background (cont.)• From patients’ side pain continues to represent the main limiting factor to a large-scale use of outpatient hysteroscopy
  • 5. Office Based Hysteroscopy(OBH) facts• Only 15% of gynecologists in the United States routinely perform office hysteroscopy to evaluate intrauterine pathology. Reimbursement Equipment
  • 6. The OBH need• Broadening of applications’ list• Cost reduction• Becoming the gold standard for specific operations• Updating of reimbursement policies.
  • 7. Orbomed:Office Based Hysteroscopy product line• Three dimensional scissors• No need for laparoscop reposition• Easier lesion capture in moving media (saline flow)• Ready-for-sending tissue sample post-operationally
  • 8. What is the difference inORBOMED concept?VIDEO>>
  • 9. Advantages of Orbomed• Improved patient’s comfort• Eliminated need for general anesthesia• Shorten interventional procedure• Reduced overall cost
  • 10. Target CustomersPrivate/public gynecological clinics
  • 11. Applications• Polypectomy – 6M of annual visits• Adhesiolysis – 1M of Asherman Syndrome• Biopsy under direct visualization – approx. 50K of new endometrial cancer/year
  • 12. Market potential• Global Uro-Gynecological Surgical Devices Market to Reach US$1.98 Billion by 2015• Global Biopsy devices Market is expected to reach $1.4 Billion by 2018, CAGR 5% from 2011.
  • 13. Orbomed R&D plan• Within 24 months we plan to achieve fully working prototype ready for clinical trials• Planned budget $750K
  • 14. ‫‪Budget‬‬ ‫שיווק‬ ‫שונות‬ ‫%9‬ ‫ציוד‬ ‫%31‬ ‫שכר‬ ‫%3‬ ‫%24‬ ‫קבלני משנה‬ ‫%92‬ ‫חומרים וציוד‬ ‫מתכלה‬ ‫%4‬
  • 15. Thank you